BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
April 10, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells,...
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
April 09, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior...
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
March 07, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer...
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
March 06, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
February 27, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
February 07, 2024 08:00 ET
|
BriaCell Therapeutics Corp.
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with...
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
February 06, 2024 08:30 ET
|
BriaCell Therapeutics Corp.
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T...
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
January 30, 2024 22:48 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
January 04, 2024 08:45 ET
|
BriaCell Therapeutics Corp.
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cyclesPowerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular...
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
December 28, 2023 08:55 ET
|
BriaCell Therapeutics Corp.
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune...